Увійти

Готові списки джерел за темами / 159.9: 629.7(043.2) / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: 159.9: 629.7(043.2).

Статті в журналах з теми "159.9: 629.7(043.2)"

Автор: Grafiati

Опубліковано: 30 травня 2022

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "159.9: 629.7(043.2)".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Harrowfield, Jack M., Raj Pal Sharma, Brian W. Skelton, and Allan H. White. "Structural Systematics of 2/4-Nitrophenoxide Complexes of Closed-Shell Metal Ions. III 2/4-Nitrophenoxides of Univalent Heavy Metals." Australian Journal of Chemistry 51, no. 8 (1998): 735. http://dx.doi.org/10.1071/c97100.

Повний текст джерела

Анотація:

Room-temperature single-crystal X-ray studies are recorded for 2- and 4-nitrophenoxide salts of silver(I) and thallium(I), M(2-np) and Tl(4-np) (anhydrous), and Ag(4-np).H2O. Ag(2-np) is monoclinic, P21/c, a 9·012(4), b 5·743(5), c 12·594(5) Å, β 104·34(4)°, Z = 4; conventional R on |F| was 0·042 for No 1378 independent ‘observed’ (I > 3σ(I)) reflections. Tl(2-np) is monoclinic, C2/c, a 27·250(3), b 3·712(1), c 15·147(3) Å, β 114·41(1)°, Z = 8, R 0·025 for No 1346. Ag(4-np).H2O is monoclinic, P21/a, a 5·613(6), b 13·191(7), c 9·844(5) Å, β 92·50(6)°, Z = 4, R 0 ·033 for No 622. Tl(4-np) is

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Effendy, Warren J. Grigsby, Robert D. Hart, Colin L. Raston, Brian W. Skelton, and Allan H. White. "Structural Characterization of Some Novel Oxidation Products of Triphenylstibine." Australian Journal of Chemistry 50, no. 6 (1997): 675. http://dx.doi.org/10.1071/c96042.

Повний текст джерела

Анотація:

Room-temperature single-crystal X-ray structural characterizations of two oxidation products of triphenylstibine of the form XPh3SbOSbPh3X are recorded for X = Cl, NO3. ClPh3SbOSbPh3Cl is monoclinic, P 21/c, Z = 4 f.u., a 9·109(4), b 19·809(8), c 19·30(2) Å, β 109·27(5)°, conventional R on F being 0·038 for No 4431 ‘observe’ (I > 3σ(I)) independent reflections. In this complex, Sb-O-Sb is quasi-linear, 173·1(3)°, in contrast to the previously recorded benzene solvate, in which it is 139·0(3)°; in the nitrate, [(O2NO)Ph3SbOSbPh3(ONO2)], triclinic, P-1, Z = 2 f.u., a 15·609(5), b 13·238(4), c

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Nurbaeva, K., T. Reshetnyak, F. Cheldieva, M. Cherkasova, E. Samarkina, and A. Lila. "AB0116 NEW INFLAMMATORY MARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1188.1–1189. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1331.

Повний текст джерела

Анотація:

BackgroundThromboinflammation is a pathological process that is associated with uncontrolled inflammation, leading to hypercoagulability and thrombotic complications. Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are prototypical chronic thromboinflammatory diseases. Neutrophils are important cells in the development of systemic inflammation and thrombosis. Neutrophil reactivity (NEUT-RI), neutrophil granularity (NEUT-GI), immature granulocytes (IG), and neutrophil-to-lymphocyte ratio (NLR) are considered as inflammatory markers.ObjectivesTo determine the role of param

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Singh, V., J. Krishnamurthy, O. Frankfurt, et al. "The Effect of Increasing CD34+ Cell Doses on Time to Engraftment after Autotransplantation for Hematologic Malignancies." Blood 112, no. 11 (2008): 1115. http://dx.doi.org/10.1182/blood.v112.11.1115.1115.

Повний текст джерела

Анотація:

Abstract It is thought that 2 x 106/kg is the minimum CD34+ cell dose needed for autotransplantation, while the ideal dose is generally accepted to be 5 x 106/kg. Whether infusing cell doses higher than 5 x 106/kg offers additional benefit is unknown. The relationship between time to standard engraftment endpoints (0.5 x 109/L Neutrophils – ANC 0.5, 1 x 109/L neutrophils – ANC 1.0, 20 x 109/L platelets – PLT 20, and 50 x 109/L platelets – PLT 50) and the CD34+ cell doses infused was explored in 754 autografts performed for malignant diseases in adult patients: 32 leukemia, 195 lymphoma, 514 my

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Marincowitz, Carl, Omar Bouamra, Tim Coates, et al. "1427 The effect of the COVID-19 pandemic on major trauma presentations and patient outcomes in English hospitals." Emergency Medicine Journal 39, no. 12 (2022): A960.2—A964. http://dx.doi.org/10.1136/emermed-2022-rcem2.2.

Повний текст джерела

Анотація:

Aims, Objectives and BackgroundThere is evidence that COVID-19 ‘lockdowns’ may have contributed to increased non-accidental injury, domestic violence and self-harm related to deteriorating mental health. Internationally, there is also evidence that the diversion of health care resources may led to worse outcomes for patients presenting with major trauma. There has been no previous national evaluation of ‘lockdown’ measures impact on the characteristics, treatment pathways and outcomes of trauma patients in EnglandWe aimed to assess the impact of successive lockdowns on the volume, demographics

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Winkler, Jeannine, Sabine Kroiss, Margaret L. Rand, Markus Schmugge, and Oliver Speer. "Activation of Caspases-8 and -9 Occurs In Platelets From Children with Immune, but Not Chemotherapy-Related, Thrombocytopenia." Blood 116, no. 21 (2010): 3700. http://dx.doi.org/10.1182/blood.v116.21.3700.3700.

Повний текст джерела

Анотація:

Abstract Abstract 3700 Apoptotic-like processes in platelets are similar to those observed during apoptosis in the cytoplasm of nucleated cells: activation of caspase-8, caspase-9, and caspase-3, loss of mitochondrial inner membrane potential, and externalization of phosphatidylserine (PS) (Leytin et al, Br J Haematol 2006; Lopez et al, J Thromb Haemost 2009). We recently showed that platelets in pediatric primary immune thrombocytopenia (ITP) have activated caspase-3 (aCASP3) and externalized PS, both of which were reduced after IVIg administration (Speer et al, Blood 2008;112: 3417). To gain

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Kokhno, Alina V., Elena A. Mikhailova, Elena N. Parovichnikova, et al. "Splenectomy In Patients with MDS." Blood 116, no. 21 (2010): 1879. http://dx.doi.org/10.1182/blood.v116.21.1879.1879.

Повний текст джерела

Анотація:

Abstract Abstract 1879 Splenectomy in patients with MDS is a treatment option that is beeing applied very rare [Steensma D., et al, Leuk Res.,2003; Bourgeosis E., et al, Leukemia, 2001]. There are anecdotal reports with very few patients demonstrating its efficacy. In most cases splenectomy was indicated for MDS patients with immune related thrombocytopenia. Here we would like to report the results of 33 splenectomies in patients with MDS who have been treated in our Center during 1994–2010. Within this period of follow-up totally 155 patients were diagnosed with different forms of MDS, 35% of

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Su, Liyu, Zaisheng Ye, Changhua Zhuo, et al. "Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): OS analysis results of the SYLT-023." Journal of Clinical Oncology 43, no. 4_suppl (2025): 450. https://doi.org/10.1200/jco.2025.43.4_suppl.450.

Повний текст джерела

Анотація:

450 Background: Tisle is an anti-PD-1 antibody. The combination of Tisle + XELOX/FP is a first-line treatment of AGC in China. Both irinotecan and paclitaxel have also shown antitumor activity in AGC. In this phase I/II study, we explore the safety, tolerability, and efficacy of Tisle + POFI as first-line treatment of HER-2 negative, pMMR AGC. Methods: In a phase I dose finding study using a standard 3+3 design, subjects received four escalating dose levels (dl) of irinotecan/paclitaxel (mg/m 2 ): 135/45 (dl #1), 150/45 (dl #2), 135/67.5 (dl #3), and 135/90 (dl #4) in combination with tisle 20

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Patel, Priti, Mayra Telesca, and De-Hui Ku. "The Comparison of Fibrin Monomer (FM) Performance to Other Activation Markers (TAT, PF1.2 and DD)." Blood 118, no. 21 (2011): 5259. http://dx.doi.org/10.1182/blood.v118.21.5259.5259.

Повний текст джерела

Анотація:

Abstract Abstract 5259 In this study, we attempted to determine the performance of the soluble fibrin monomer complex (SFMC) test in comparison to known activation markers, such as prothrombin fragment 1.2 (PF1.2), thrombin antithrombin complex (TAT) and d-dimer (DD). We have used the STA(R)-Liatest FM and STA(R)-Liatest D-Di kits to measure the SFMC and d-dimer levels. A total of 25 patients were included in this study. The data and demographic information are shown in the table below. ID GENDER AGE FM TAT PF1.2 D-dimer 1 M 66 0.42 2.3 1988 0.05 2 F 31 27.93 >60.0 >12000 2.39 3 F 24 3.4

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Sho, Takuya, Goki Suda, Yoshiya Yamamoto, et al. "Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150." Cancers 14, no. 16 (2022): 3938. http://dx.doi.org/10.3390/cancers14163938.

Повний текст джерела

Анотація:

The IMbrave150 trial demonstrated the high efficacy and safety of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma (HCC). In this multicenter study, the efficacy of this combination and its effect on liver functional reserve were evaluated in patients not meeting the eligibility criteria of IMbrave150. Of 115 patients with unresectable HCC treated with atezolizumab and bevacizumab between October 2020 and January 2022, 72 did not meet the eligibility criteria of IMbrave150, most frequently due to a history of systemic therapy (60/72), platelet counts < 75 × 109/L (7/72

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Ibrahim, Mustafa M., Marwa M. Attia, Hanadi B. Baghdadi, and Mohamed Abdelsalam. "First report of Kudoa species (Myxozoa, Multivalvulida) infection in purple-spotted Bigeye (Priacanthus tayenus) from the Saudi Arabian Gulf." PLOS ONE 19, no. 1 (2024): e0295668. http://dx.doi.org/10.1371/journal.pone.0295668.

Повний текст джерела

Анотація:

The purple-spotted bigeye, Priacanthus tayenus, is a marine benthic fish native to the Indian and Pacific Oceans, including the Arabian Gulf in Saudi Arabia. This study identified a myxozoan parasite infecting wild P. tayenus from the Saudi Arabian Gulf. These parasites produced spherical to ovoid-shaped, white plasmodia enclosed within pseudocysts in the fish musculature. The annual infection rate was 5.1%, with the highest prevalence in summer (7.6%), followed by spring (6%), and autumn (2.5%), while no infections were observed in winter. The number of plasmodia per fish ranged from 100 to 1

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Marques, M. L., N. Pereira Da Silva, D. Van der Heijde, et al. "POS0974 LOW DOSE COMPUTED TOMOGRAPHY HOUNSFIELD UNITS: A RELIABLE METHODOLOGY FOR ASSESSING CHANGES IN VERTEBRAL BONE DENSITY IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 794.2–795. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2276.

Повний текст джерела

Анотація:

BackgroundAssessing local vertebral bone loss in radiographic axial spondyloarthritis (r-axSpA) poses challenges, namely because Dual-energy X-ray absorptiometry (DXA) only allows assessment of lumbar vertebrae. The measurement of Computed Tomography (CT) vertebral Hounsfield Units (HU) has been shown to correlate with vertebral bone density as measured by DXA in trauma patients. We have recently reported the excellent reliability of low dose CT (ldCT) HU measurements from C3 to L5 in patients with r-axSpA1; however, HU change scores have never been studied.ObjectivesTo describe ldCT HU change

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Lisukov, Igor, Alexander Kulagin, Alexey Maschan, et al. "Effect of Eculizumab on Physician-Reported Symptoms in the Russian Cohort of the Paroxysmal Nocturnal Hemoglobinuria (PNH) International Registry." Blood 124, no. 21 (2014): 5163. http://dx.doi.org/10.1182/blood.v124.21.5163.5163.

Повний текст джерела

Анотація:

Abstract Background: Paroxysmal nocturnal hemoglobinuria is a rare clonal hematopoietic stem cell disease that can lead to life-threatening complications including thrombotic events (TE), chronic kidney disease (CKD) and pulmonary hypertension. In 2011 the International PNH Registry was implemented in the Russian PNH cohort to assess the natural history of PNH and the effects of treatment with eculizumab. Aims:We aim to evaluate the change from baseline to last follow-up in physician-reported symptoms, LDH and hemoglobin concentration in treated and untreated PNH patients. Design and methods:

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Rivera Teran, V., D. Alpizar-Rodriguez, S. Sicsik, et al. "FRI0546 GENDER DIFFERENCES OF RHEUMATIC DISEASES IN MEXICAN POPULATION: DATA FROM THE MEXICAN BIOLOGICS REGISTRY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 874–75. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6091.

Повний текст джерела

Анотація:

Background:Most autoimmune diseases are more prevalent in women. Symptom severity, disease progression, response to therapy and overall survival differ between males and females with rheumatic diseases.Objectives:To identify the characteristics of autoimmune diseases presentation and treatment between male and female population using information from the Mexican Adverse Events Registry (BIOBADAMEX).Methods:BIOBADAMEX is a Mexican ongoing cohort that collects the information of patients using biologic and biosimilar drugs since 2016. For this study we included all patients enrolled in the regis

Стилі APA, Harvard, Vancouver, ISO та ін.

15

He, Xin, Kyriakie Sarafoglou, Patricia Y. Fechner, et al. "Changes in Adrenal and Gonadal Androgens After 14-Day Treatment With CRF1 Receptor Antagonist, Crinecerfont (NBI-74788), in Men With Classic 21-Hydroxylase Deficiency." Journal of the Endocrine Society 5, Supplement_1 (2021): A78. http://dx.doi.org/10.1210/jendso/bvab048.157.

Повний текст джерела

Анотація:

Abstract Background: Congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency (21OHD) causes cortisol insufficiency and androgen excess. A phase 2 trial of crinecerfont, a CRF1 receptor antagonist, in 18 adults with 21OHD showed prominent decreases in ACTH, 17-hydroxyprogesterone, and androstenedione (A4), and in women, testosterone (T), after 14 days of treatment. In men with 21OHD, T derives from both adrenals and testes; in poor disease control, A4/T ratio is elevated due to disproportionately increased adrenal A4 production and decreased testicular T production. We sought to

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Hamdi, O., M. Sellami, S. Miladi, et al. "POS1491-HPR MENTAL HEALTH OUTCOMES AMONG HEALTH CARE WORKERS DURING THE CORONAVIRUS-19 PANDEMIC." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1030.2–1030. http://dx.doi.org/10.1136/annrheumdis-2021-eular.783.

Повний текст джерела

Анотація:

Background:The coronavirus-19 (COVID-19) pandemic is having negative effects on societies’ mental health, particularly health care workers who are exposed to tremendous psychological stress.Objectives:To assess the magnitude of mental health outcomes among health care workers treating patients exposed to COVID-19.Methods:This cross-sectional study collected demographic data and mental health measurements from health workers in different hospitals using an online questionnaire. Participants were also asked to complete the 9-item Patient Health Questionnaire (PHQ-9), the 7-item Insomnia Severity

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Dombret, Hervé, Alexandra Coelho, Laurène Fenwarth, et al. "Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study." Blood 144, Supplement 1 (2024): 2424. https://doi.org/10.1182/blood-2024-207226.

Повний текст джерела

Анотація:

Introduction. AML treatment options have been recently enriched. New agents like gemtuzumab ozogamicin (GO), FLT3 or IDH inhibitors, or CPX-351 have been approved for some patient subsets. Less-intensive options, like the AZA-VEN combination, are used in older/unfit patients. However, while treatments and indications are standardized, their choice is not, depending on often-subjective factors. This makes observational studies so important to describe the real-life management and outcomes of AML patients. Methods. In 2022, the ALFA group initiated a 2-cohort (newly diagnosed, relapsed/refractor

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Rivera Teran, V., M. Pérez Rodríguez, D. Alpizar-Rodriguez, et al. "AB1229 SAFETY OF BIOSIMILAR ETANERCEPT IN THE TREATMENT OF RHEUMATIC DISEASES: DATA FROM THE MEXICAN ADVERSE EVENTS REGISTRY (BIOBADAMEX)." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1905.1–1906. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3819.

Повний текст джерела

Анотація:

Background:Access to biosimilar drugs in Mexico started on 2014. Although biosimilar drugs safety has proved comparability to originator drugs on trials, information about its safety on real-life data is limited.Objectives:To compare safety in terms of adverse events of biosimilar etanercept (BEt) to originator etanercept (OEt) using information from the Mexican Adverse Events Registry (BIOBADAMEX).Methods:BIOBADAMEX is a Mexican cohort that collects the information of biologic and biosimilar drugs used in patients with rheumatic diseases in public and private practice since 2016. Patients enr

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Turhan, Şeref, Elif Gören, Ahmed M. K. Garad, et al. "Radiometric measurement of lignite coal and its by-products and assessment of the usability of fly ash as raw materials in Turkey." Radiochimica Acta 106, no. 7 (2018): 611–21. http://dx.doi.org/10.1515/ract-2017-2863.

Повний текст джерела

Анотація:

Abstract Lignite coal (LC) is a key energy source for electricity generation in Turkey. During lignite burning, huge amounts of fly ash (FA), bottom ash and slag are produced as by-products which contain radionuclides in the natural radioactive series of uranium and thorium, and radioactive potassium. These radionuclides may lead to radiological exposure of workers and the public and cause environmental problems. Therefore, finding diverse uses for the by-products in the construction sector and earthwork applications has considerable economic and environmental importance. In this study, the ac

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Martin Lopez, M., B. Joven-Ibáñez, and J. L. Pablos. "SAT0428 IMPACT OF DOSE ESCALATION OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL-WORLD SETTING." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1168.2–1169. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6579.

Повний текст джерела

Анотація:

Background:Secukinumab (SEC) has provided efficacy in clinical trials in patients with psoriatic arthritis (PsA). In PsA patients, a gain in response has been suggested by dose escalation from 150 to 300 mg in the open phase of the FUTURE study1.Objectives:To analyze the usefulness of dose escalation of SEC from 150 to 300 in patients with non-responding PsA to 150 mg in real-world setting.Methods:Multicentric observational, longitudinal, retrospective study conducted in a tertiary hospital between January 2016 and December 2019. Patients with PsA (CASPAR criteria) receiving at least one dose

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Sasaki, Koji, Ildefonso Ismael Rodriguez-Rivera, Hagop M. Kantarjian, et al. "Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase." Blood 124, no. 21 (2014): 4538. http://dx.doi.org/10.1182/blood.v124.21.4538.4538.

Повний текст джерела

Анотація:

Abstract Background: Total lymphocyte count (TLC) has been shown to correlate with outcomes in patients (pts) with acute leukemia. The clinical correlation to TLC in pts with chronic myeloid leukemia in chronic phase (CML-CP) who were treated with a tyrosine-kinase inhibitor (TKI) is unclear. Methods: Lymphocyte data in pts with newly diagnosed CML-CP who were enrolled in consecutive or parallel clinical trials with front-line imatinib (IM), nilotinib (Nilo), or dasatinib (Dasa) were collected at the time of diagnosis, and 3 and 6 months (M) after the start of TKI. Relative lymphocytrosis (RLC

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Shanavas, Mohamed, Hans A. Messner, Suzanne Kamel-Reid, et al. "A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation." Blood 122, no. 21 (2013): 5501. http://dx.doi.org/10.1182/blood.v122.21.5501.5501.

Повний текст джерела

Анотація:

Abstract Abstract 5501 Relapse is a major cause of treatment failure of allogeneic hematopoietic cell transplantation (HCT) for Chronic Myeloid Leukemia (CML). DLI (Donor lymphocyte infusion) and TKI (Tyrosine Kinase inhibitors) are the two standard treatment options in this setting but reports comparing their long-term outcomes are scarce. Between 1993 and 2012, 28 patients underwent DLI and 18 patients received TKI for chronic or advanced phase relapse of CML at our institution. Chronic hematologic, cytogenetic and molecular relapses were considered as chronic phase relapses. Accelerated pha

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Guebels, Charlotte P., Lynn C. Kam, Gianni F. Maddalozzo, and Melinda M. Manore. "Active Women before/after an Intervention Designed to Restore Menstrual Function: Resting Metabolic Rate and Comparison of Four Methods to Quantify Energy Expenditure and Energy Availability." International Journal of Sport Nutrition and Exercise Metabolism 24, no. 1 (2014): 37–46. http://dx.doi.org/10.1123/ijsnem.2012-0165.

Повний текст джерела

Анотація:

It is hypothesized that exercise-related menstrual dysfunction (ExMD) results from low energy availability (EA), defined as energy intake (EI)—exercise energy expenditure (EEE). When EI is too low, resting metabolic rate (RMR) may be reduced to conserve energy.Purpose:To measure changes in RMR and EA, using four methods to quantify EEE, before/after a 6-month diet intervention aimed at restoring menses in women with ExMD; eumenorrheic (Eumen) active controls (n = 9) were also measured.Methods:Active women with ExMD (n = 8) consumed +360 kcal/d (supplement) for 6 months; RMR was measured 2 time

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Oztas, M., M. Bektaş, I. Karacan, et al. "AB1082 FREQUENCY AND SEVERITY OF COVID-19 IN PATIENTS WITH VARIOUS RHEUMATIC DISEASES TREATED REGULARLY WITH COLCHICINE OR HYDROXYCHLOROQUINE." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1660.2–1661. http://dx.doi.org/10.1136/annrheumdis-2022-eular.83.

Повний текст джерела

Анотація:

BackgroundSeveral anti-inflammatory drugs which were targeted different mechanisms and investigated for both prevention and treatment for COVID-19.ObjectivesThe current study aimed to investigate whether patients regularly using colchicine or hydroxychloroquine (HCQ) have an advantage of protection from COVID-19 or developing less severe disease.MethodsPatients who were taking colchicine or HCQ regularly for a rheumatic disease including Familial Mediterranean Fever, Behçet’s syndrome, Systemic Lupus Erythematosus, Rheumatoid Arthritis and Sjogren’s syndrome as well as their healthy household

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Monteith, Bethany E., Esther Masih-Khan, Eshetu G. Atenafu, et al. "Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience." Blood 126, no. 23 (2015): 5361. http://dx.doi.org/10.1182/blood.v126.23.5361.5361.

Повний текст джерела

Анотація:

Abstract Background The incorporation of novel agents (NA) for multiple myeloma (MM) has improved the response rates (RR), overall survival (OS), and progression free survival (PFS) when compared to conventional agents (CA). Unfortunately, relapse is inevitable and few studies focus on patterns of relapse, especially in non-transplant patients (pts). We aim to describe the different patterns of relapse in non-transplant MM pts and determine if any pre-treatment clinical or disease characteristics can predict the patterns relapse. We will evaluate whether NA treated pts have higher rates of agg

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Chahoud, Jad, Hagop M. Kantarjian, Farhad Ravandi, et al. "The Impact of 20q Deletion on Clinical Presentation, Treatment Response and Survival in Patients with Acute Myeloid Leukemia (AML): The University of Texas MD Anderson Cancer Center Experience." Blood 126, no. 23 (2015): 1369. http://dx.doi.org/10.1182/blood.v126.23.1369.1369.

Повний текст джерела

Анотація:

Abstract Background: Karyotype classification is one of the strongest independent prognostic indicators in AML. The majority of recurring chromosomal aberrations are associated with an individual prognosis, other less frequent like the Del (20q), have been minimally evaluated and classified as intermediate risk in AML. Multiple studies established isolated 20q deletion as a good prognostic marker in MDS, with lower AML transformation rates and longer median overall survival (OS) in comparison with complex 20q deletion. Objective: The aim of this study is to determine the frequency and the impa

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Warmansyah, Jhoni, Afriyane Ismandela, Dinda Fatma Nabila, et al. "Smartphone Addiction, Executive Function, and Mother-Child Relationships in Early Childhood Emotion Dysregulation." JPUD - Jurnal Pendidikan Usia Dini 17, no. 2 (2023): 241–66. http://dx.doi.org/10.21009/jpud.172.05.

Повний текст джерела

Анотація:

Early childhood emotional dysregulation is critical in recognizing and preventing psychological well-being disorders, laying the groundwork for developing healthy emotional behaviors early on. This study aims to determine the direct influence of smartphone addiction, executive function, and the mother-child relationship on emotional dysregulation in early childhood in West Sumatra. This research method is a quantitative survey. The data collection technique in this research uses a questionnaire design on 309 parents who were selected using a simple random sampling method. This data processing

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Arndt, C. A., D. S. Hawkins, J. A. Stoner, et al. "Randomized phase III trial comparing vincristine, actinomycin, cyclophosphamide (VAC) with VAC/V topotecan/cyclophosphamide (TC) for intermediate risk rhabdomyosarcoma (IRRMS). D9803, COG study." Journal of Clinical Oncology 25, no. 18_suppl (2007): 9509. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.9509.

Повний текст джерела

Анотація:

9509 Background: IRRMS was defined as nonmetastatic alveolar (A) RMS or undifferentiated sarcoma (UDS); stage (stg) 2 and 3, group (gr) III embryonal (E) RMS; stg 4 ERMS <10y. IRRMS had a 5 yr failure free survival (FFS) of 64% on IRS IV. Since T alone and with C has significant activity in RMS, we tested whether alternating VAC/VTC improved FFS for IRRMS compared with VAC alone. Methods: Patients (pts) < 50 y with IRRMS with adequate organ function were randomized to 39 wks of VAC (V=1.5 mg/m2, A=0.045 mg/kg, C=2.2 g/m2 q 3 wk) vs VAC alternating with VTC (T=0.75 mg/m2/d ×5, C=250 mg/m2

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Moyers, Justin Tyler, Danielle Brazel, Priyanka Kumar, et al. "Abstract 2184: Landscape of genomic alterations of ultra-rare sarcomas (URS) from 1,079 patients in the AACR GENIE real world database: Clinical implications." Cancer Research 82, no. 12_Supplement (2022): 2184. http://dx.doi.org/10.1158/1538-7445.am2022-2184.

Повний текст джерела

Анотація:

Abstract Introduction: Sarcomas are heterogenous tumors of more than 150 different tumor types. Recently, 56 soft tissue (ST-URS) and 21 bone (B-URS) sarcomas were classified as URS based on incidence of less than 1 in a million by the Connective Tissue Oncology Society. There is only one histology-based treatment approved in URS. Methods: AACR GENIE database cBioPortal were accessed. Individual alterations annotated by OncoKB therapeutic evidence level, TCGA PanCancer pathway alterations, and demographic data were gathered. Detailed cancer type was reclassified into genomically distinct disea

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Combe, B., Y. Tanaka, P. Emery, et al. "POS0679 CLINICAL OUTCOMES UP TO WEEK (W) 48 IN THE ONGOING FILGOTINIB (FIL) LONG-TERM EXTENSION (LTE) TRIAL OF RHEUMATOID ARTHRITIS (RA) PATIENTS (pts) WITH INADEQUATE RESPONSE (IR) TO METHOTREXATE (MTX) INITIALLY TREATED WITH FIL OR ADALIMUMAB (ADA) DURING THE PHASE 3 PARENT STUDY (PS)." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 615–16. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1641.

Повний текст джерела

Анотація:

BackgroundThe preferential Janus kinase-1 inhibitor FIL is approved for treatment of moderate to severe active RA in Europe and Japan.ObjectivesEfficacy and safety of FIL were assessed in pts with IR to MTX who completed a Phase 3 trial (NCT02889796)1 and enrolled in an LTE (NCT03025308).MethodsPts completing the PS1 on study drug were eligible to enter the LTE (data cutoff: June 1, 2020). Median exposure: 2.2 years (y). Efficacy data to W48 are reported for 4 treatment groups (all with background MTX): pts receiving FIL 200 mg (FIL200) or FIL 100 mg (FIL100) in the PS and continuing their dos

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Law, Jeanna Wallenta, Zartash Gul, Anna Berry, et al. "Abstract 6259: Molecular biomarker testing and targeted therapy patterns in patients with acute myelogenous leukemia (AML): A real-world data analysis." Cancer Research 82, no. 12_Supplement (2022): 6259. http://dx.doi.org/10.1158/1538-7445.am2022-6259.

Повний текст джерела

Анотація:

Abstract Background and Objective: Molecular testing and targeted treatments for patients (pts) diagnosed with AML have evolved in recent years. Real-world testing patterns, including next-generation sequencing (NGS), and clinical management of pts with AML were analyzed in 2 large U.S. community health systems. Methods: Pts &gt;18 years, diagnosed with AML from January 1, 2015 to December 31, 2020, were identified in a database containing clinical and genomic data from integrated community delivery networks. Study end was March 31, 2021, allowing for 3 months minimum follow up. Actionable

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Rivera Teran, V., D. X. Xibille Friedmann, D. Vega-Morales, et al. "AB1358 BIOLOGIC TREATMENT SUSPENSION AND ASSOCIATED FACTORS IN PATIENTS WITH RHEUMATIC DISEASES DURING THE COVID-19 PANDEMIC: DATA FROM MEXICAN ADVERSE REGISTRY (BIOBADAMEX)." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1909.2–1910. http://dx.doi.org/10.1136/annrheumdis-2023-eular.5232.

Повний текст джерела

Анотація:

BackgroundThe COVID-19 pandemic triggered serious challenges in the treatment of chronic diseases due to the lack of access to medical attention. Patients with rheumatic diseases (RD) must have adequate treatment compliance in order to reach and maintain remission or low activity of their diseases. Treatment suspension because of non-medical reasons might lead to disease activation and organ damage.ObjectivesIdentify the frequency of biologic treatment (bDMARD) suspension in patients with RD during the COVID-19 pandemic and determine the associated factors for suspension.MethodsIn this study w

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Martín Moro, Fernando, Ana Jiménez Ubieto, Marina Gomez Llobell, et al. "A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms." Blood 144, Supplement 1 (2024): 4478. https://doi.org/10.1182/blood-2024-212008.

Повний текст джерела

Анотація:

Background: Plasmablastic neoplasms are rare and aggressive tumors that exhibit biological complexity and poor prognosis despite intensive approaches. Our aims were to evaluate the prognostic impact of clinical and biological variables in a series of plasmablastic neoplasms and to design a prognostic score. Besides, we analyzed the first-line therapeutic approach. Methods: Multicentric retrospective study within the Spanish Lymphoma Group (GELTAMO) including de novo plasmablastic neoplasms. Clinical, biological and therapeutic variables were analyzed, highlighting the evaluation of 17 markers

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Belli, Carolina, Ronald Feitosa Pinheiro, Maria Gabriela Flores, et al. "Clinical Characteristics and Prognosis in South-American Patients with Myelodysplastic Syndrome: A Multicenter Study." Blood 124, no. 21 (2014): 4651. http://dx.doi.org/10.1182/blood.v124.21.4651.4651.

Повний текст джерела

Анотація:

Abstract There are previous reported data describing differences between European and Asian patients with Myelodysplastic Syndromes (MDS), and little is known about South-American (SA) patients. Our aim was to describe clinical characteristic of SA MDS population, to compare our series with diverse ethnicity, to evaluate scoring systems and prognostic factors. We retrospectively analysed a series of 1080 patients with de novo MDS (1981-2014) from Argentine (Ar-635), Brazil (Br-345), and Chile (Ch-100). Patients were classified following FAB and WHO criteria, excluding patients with bone marrow

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Erinjeri, Joseph Patrick, Muhammad S. Beg, Mohamed Bouattour, et al. "Outcomes by baseline tumor burden using the 6-and-12 score in EMERALD-1: A phase 3 study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolization (TACE) in embolization-eligible unresectable hepatocellular carcinoma (uHCC)." Journal of Clinical Oncology 43, no. 16_suppl (2025): 4083. https://doi.org/10.1200/jco.2025.43.16_suppl.4083.

Повний текст джерела

Анотація:

4083 Background: In EMERALD-1 (NCT03778957), D + B + TACE significantly improved progression-free survival (PFS) vs TACE in participants (pts) with embolization-eligible uHCC. Tumor burden is a prognostic factor in HCC. Prior analyses showed improvements in PFS with D + B + TACE vs TACE in pts who met or exceeded the up-to-7 criterion (a measure based on tumor number and size), and in those with max tumor diameters of < 10 cm or ≥10 cm. The 6-and-12 score measures tumor burden based on tumor number and size. We assessed outcomes in EMERALD-1 by baseline tumor burden using the 6-and-12 score

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Hart, Lowell, Seock-Ah Im, Sara Tolaney, et al. "Abstract PS02-01: Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials." Cancer Research 84, no. 9_Supplement (2024): PS02–01—PS02–01. http://dx.doi.org/10.1158/1538-7445.sabcs23-ps02-01.

Повний текст джерела

Анотація:

Abstract Background: Ribociclib (RIB) + endocrine therapy (ET) showed statistically significant progression-free survival (PFS) and overall survival (OS) benefits in MONALEESA-2, -3, and -7 in patients (pts) with HR+/HER2− advanced breast cancer (ABC). Here, we report efficacy, safety, and quality of life (QOL) with RIB + ET in elderly pts in the MONALEESA trials. Methods: Data were pooled from the MONALEESA-2, -3, and -7 trials of pre- and postmenopausal pts with HR+/HER2− ABC treated with first-line RIB + ET or placebo (PBO) + ET. The tamoxifen cohort in MONALEESA-7 and pts with early relaps

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Galindez, E., D. Prieto-Peña, J. L. Martín-Varillas, et al. "AB0768 TREATMENT WITH TOFACITINIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF 87 PATIENTS IN CLINICAL PRACTICE." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1682.1–1682. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2903.

Повний текст джерела

Анотація:

Background:Tofacitinib (TOFA) is the first JAKi approved for psoriatic arthritis (PsA) in Europe (July 2018). TOFA has shown efficacy in refractory patients to anti-TNF in Randomized Clinical Trials (RCT) (Gladman D. NEJM 2017; 377: 1525-36).Objectives:To assess efficacy and safety of TOFA in clinical practice (CP). To compare the profile of CP with RCTMethods:Study of 87 patients of CP with PsA treated with TOFA; Results are expressed as percentage, mean±SD or median [IRQ].Results:87 patients (28♀/59♂), mean age of 52.8±11.4 years (Table 1). Pattern of joint involvement was: peripheral (n=60)

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Baron, Frederic, Myriam Labopin, Andrew Peniket, et al. "RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT." Blood 124, no. 21 (2014): 545. http://dx.doi.org/10.1182/blood.v124.21.545.545.

Повний текст джерела

Анотація:

Abstract AN and MM are co-senior authors. Background. Fludarabine plus busulfan (FB) and fludarabine plus melphalan (FM) are two widely used reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation (allo-SCT). Patients and Methods. In the current survey, we compared transplantation outcomes in a cohort of 394 acute myeloid leukemia (AML) patients given grafts from HLA-identical siblings after FB (n=218; with a total busulfan dose ranging between 7.1 and 8.9 mg/kg p.o., or between 6.0 and 6.9 mg/kg i.v.) or FM (n=176; with a total melphalan dose rangi

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Derks Eduarda Wilhelmina, M., M. te Groen, L. Derikx, I. Nagtegaal, and F. Hoentjen. "P0445 High risk of colorectal cancer after high-grade dysplasia in Inflammatory Bowel Disease patients." Journal of Crohn's and Colitis 19, Supplement_1 (2025): i955—i956. https://doi.org/10.1093/ecco-jcc/jjae190.0619.

Повний текст джерела

Анотація:

Abstract Background Colonic high-grade dysplasia (HGD) is the highest-risk precursor of colorectal cancer (CRC) in inflammatory bowel disease (IBD) patients with reported incidence rates of 1.0-3.5%.1-4 Data on metachronous CRC risk after HGD in IBD are limited and outdated. The aim of this study was to determine the long-term risk of CRC and colorectal neoplasia (including indefinite for dysplasia, low-grade dysplasia, HGD and CRC) after a first diagnosis of HGD in IBD, and to assess HGD treatment strategies. Methods In this nationwide retrospective cohort study, patients with both a colonic

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Portuguese, Andrew J., Aya Albittar, Emily C. Liang, et al. "Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting." Blood 142, Supplement 1 (2023): 2131. http://dx.doi.org/10.1182/blood-2023-172978.

Повний текст джерела

Анотація:

CD19 CAR-T therapy has revolutionized the management of high-risk and relapsed/refractory (R/R) large B-cell lymphoma (LBCL) but remains limited by significant toxicities leading to morbidity/mortality and high resource utilization. Single-arm studies have suggested differences in efficacy and toxicity across FDA-approved CD19 CAR-T products. A matching-adjusted indirect treatment comparison showed comparable efficacy and more favorable safety with lisocabtagene maraleucel (liso-cel) compared to axicabtagene ciloleucel (axi-cel), but was limited to clinical trial patients (pts) and suffered fr

Стилі APA, Harvard, Vancouver, ISO та ін.

41

JE, Shitaye, I. Parmova, L. Matlova, et al. "Mycobacterial and Rhodococcus equiinfections in pigs in theCzechRepublicbetween the years 1996 and 2004: the causal factors and distribution of infections in the tissues." Veterinární Medicína 51, No. 11 (2012): 497–511. http://dx.doi.org/10.17221/5584-vetmed.

Повний текст джерела

Анотація:

Between 1996 and 2004, tissue samples from 3&nbsp;630 slaughtered pigs were examined by gross examination, microscopy after the Ziehl-Neelsen (ZN) staining of homogenised tissues for the detection of acid-fast rods (AFR) and by culture for the presence of mycobacteria and Rhodococcus equi: 1&nbsp;781 head lymph nodes (ln), 1&nbsp;123&nbsp;mesenteric ln, 54 pulmonary ln, 32 inguinal ln, 562 non-identified ln and 78 samples of tissues from parenchymatous organs (liver, spleen and kidneys). Tuberculous/tuberculoid lesions were not detected in 249 (6.9%) animals slaughtered due to

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Niyazov, Alexander, Monika Izano, Colden Johanson, et al. "Abstract P2-09-05: Germline BRCA1/2 mutation testing in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC): A real-world study in the Syapse Learning Health Network (LHN)." Cancer Research 82, no. 4_Supplement (2022): P2–09–05—P2–09–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-p2-09-05.

Повний текст джерела

Анотація:

Abstract Background: Germline (g)BRCA1/2 mutations represent approximately 5% of metastatic breast cancer. Poly ADP-ribose polymerase inhibitors (PARPi) have shown improved clinical outcomes, a manageable toxicity profile, and favorable patient (pt)-reported outcomes versus chemotherapy in pts with gBRCA1/2 mutated HER2- locally advanced or metastatic breast cancer. With the advent of PARPi, clinical guidelines have broadened eligibility criteria for gBRCA1/2 testing. However, limited information is available on the impact of the COVID-19 pandemic on gBRCA1/2 testing rates. We assessed trends

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Molina Collada, J., F. Sánchez-Alonso, C. Bohórquez, et al. "OP0138 RISK OF CANCER AFTER BIOLOGIC AND TARGETED SYNTHETIC DMARDS INITIATION IN PATIENTS WITH RHEUMATIC DISEASES AND A HISTORY OF PRIOR MALIGNANCY: DATA FROM THE BIOBADASER REGISTRY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 88.2–89. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5030.

Повний текст джерела

Анотація:

BackgroundPatients with a history of cancer are routinely excluded from randomized controlled trials. As consequence, data on the safety of biologic disease modifying antirheumatic drugs (bDMARDS) and targeted synthetic (ts) DMARDs are limited. Although real world data from various national registries have not provided evidence of increased cancer recurrence, additional data from real-world registries may help to confirm safety of non-TNFi bDMARDs and tsDMARDs regarding cancer recurrence to guide treatment decisions.ObjectivesTo compare the risk of incident malignancy with exposure to differen

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Mercado, Marta Ruiz, Estrella Carrillo Cruz, Fátima de la Cruz Vicente, et al. "The Role Of 18F-FDG PET/CT For Staging and Response Assessment To Chemotherapy In Marginal Zone Lymphoma." Blood 122, no. 21 (2013): 4328. http://dx.doi.org/10.1182/blood.v122.21.4328.4328.

Повний текст джерела

Анотація:

Abstract Introduction Marginal Zone Lymphoma (MZL) is an indolent lymphoma in which the use of PET/CT is poorly explored and also controversial due to the heterogeneous 18F- FDG avidity described in these types of lymphoma. Our aim in the present study is to evaluate the role of 18F-FDG-PET/ CT (PET/CT) in comparison to CT with intravenous contrast enhancement at initial staging and response assessment to chemotherapy in these patients. Methods and Materials A retrospective single-center study that included 34 patients, diagnosed of MZL between 1998 and 2012, with at least one PET/CT available

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Rahman, P., C. T. Ritchlin, P. Helliwell, et al. "FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 776–77. http://dx.doi.org/10.1136/annrheumdis-2020-eular.387.

Повний текст джерела

Анотація:

Background:DISCOVER 1 & 2 are phase 3 psoriatic arthritis (PsA) trials investigating guselkumab (GUS), an IL-23 inhibitor that specifically binds the IL-23p19 subunit. In both studies, GUS showed significant improvement vs placebo (PBO) through week (W) 24 in the PBO-controlled period.1,2Objectives:To present integrated safety results of DISC 1 & 2 through the PBO-controlled periods.Methods:Adult patients (pts) with active PsA despite standard therapy were enrolled. All pts were biologic-naïve, except ~30% in DISC 1 with previous exposure to 1-2 TNF inhibitors. Pts were randomized to S

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Streiff, Michael, Brandyn Lau, Aditya Bhave, et al. "Underestimation of Venous Thromboembolism Risk: A Common Health Care Quality Deficit." Blood 142, Supplement 1 (2023): 5050. http://dx.doi.org/10.1182/blood-2023-185098.

Повний текст джерела

Анотація:

Venous thromboembolism (VTE) is a complication of hospitalization but not all patients are at high risk. VTE risk assessment models have been developed to identify patients whose risk is sufficient to warrant pharmacologic thromboprophylaxis. To ensure all patients are risk assessed upon admission, we implemented a mandatory risk assessment tool embedded in admission order sets in our electronic health record (EHR) system. We hypothesized that the accuracy of these risk assessments was variable. We performed a retrospective cohort study of patients discharged from the Johns Hopkins Hospital me

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Pagliuca, Simona, Régis Peffault de Latour, Franco Locatelli, et al. "Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Inherited or Acquired Bone Marrow Failure Disorders: A Report from Eurocord, Cord Blood Committee (CBC-CTIWP) and Severe Aplastic Anemia Working Party (SAAWP) of the European Group of Blood and Bone Marrow Transplantation (EBMT)." Blood 126, no. 23 (2015): 153. http://dx.doi.org/10.1182/blood.v126.23.153.153.

Повний текст джерела

Анотація:

Abstract Bone marrow failure (BMF) syndrome is a group of rare hereditary or idiopathic disorders occurring at all ages. For BMF patients under 40 years of age and having an HLA-identical related donor, allogeneic bone marrow transplantation (HSCT) is indicated. The use of cord blood transplantation (CBT) from an HLA-identical sibling donor is of interest in non-malignant disease due to the low risk of graft-versus-host disease (GVHD) associated with this type of stem cell source and the absence of risk to the donor. We analyzed outcomes of 122 children and young adults with inherited or acqui

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Wesseling, Jelle. "Abstract F1-2: Clonal evolution of DCIS to invasion." Cancer Research 83, no. 5_Supplement (2023): F1–2—F1–2. http://dx.doi.org/10.1158/1538-7445.sabcs22-f1-2.

Повний текст джерела

Анотація:

Abstract Clonal evolution of DCIS to invasion Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and, despite treatment, a small fraction (5-10%) of DCIS patients develop subsequent invasive breast cancer (IBC). If not treated, at least 3 out of 4 women with DCIS will not develop IBC1-3. This implies many women with non-progressive, low-risk DCIS are likely to carry the burden of overtreatment. To solve this DCIS dilemma, two fundamental questions need to be answered. The first question is, how the subsequent IBC is related to the initial DCIS lesion. The seco

Стилі APA, Harvard, Vancouver, ISO та ін.

49

MAŁEK, Róża, Paweł WARZYSZAK, Maria MILCZEK, et al. "Impact of physical activity in pregnant women on maternal health." Journal of Education, Health and Sport 13, no. 1 (2023): 319–25. https://doi.org/10.12775/JEHS.2023.13.01.047.

Повний текст джерела

Анотація:

<strong>MAŁEK, Róża, WARZYSZAK, Paweł, MILCZEK, Maria, ŻOŁYNIAK, Wojciech, TOMASIK, Mikołaj, HAWRANIK, Izabela, NISKI, Szymon, ŻABA, Ziemowit, LISOWSKA, Aleksandra & SKRZYPEK, Mateusz. Impact of physical activity in pregnant women on maternal health</strong><strong>. Journal of Education, Health and Sport. 202</strong><strong>3</strong><strong>;1</strong><strong>3</strong><strong>(</strong><strong>1</strong><strong>):</strong><strong>31</strong><strong>9</strong><strong>-</strong><strong>3</strong><strong>25</strong><strong>. eISSN 2391-8306. DOI</strong> <strong>http://dx.doi.

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Khaled, Yasser, Sung Choi, David A. Hanauer, and Pavan Reddy. "Nephrotic Syndrome After Allogeneic Hematopoietic Cell Transplantation: Incidence and Outcomes." Blood 114, no. 22 (2009): 3324. http://dx.doi.org/10.1182/blood.v114.22.3324.3324.

Повний текст джерела

Анотація:

Abstract Abstract 3324 Poster Board III-212 The NIH Consensus recognizes nephrotic syndrome (NS) as part of the chronic GVHD symptomatology, but this manifestation is rare and the incidence and outcomes have not been well-defined. To characterize this complication, we conducted an IRB-approved retrospective review of 626 consecutive patients (age > 16 yrs: related donor [RD], n=352; unrelated donor [URD], n=274) who underwent allogeneic hematopoietic cell transplantation (HCT) between October 2000 and December 2007 at the University of Michigan. Data abstraction was facilitated by the use o

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!